UNSPSC 51182035: Nilutamide

This classification denotes an anti-androgen with the molecular formula C12H10F3N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51G6I8B902, chemically known as 5,5-dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin but generally known as nilutamide, which bears US NIH Compound Identifier 4493. European Medicines Agency schedules Nilutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09291MIG.

UNSPSC 51182035 Nilutamide is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing vehicles and direct-buy arrangements. Recent activity shows state and local governments procuring nilutamide and related generic pharmaceuticals as part of multi-source drug procurement programs that establish framework agreements with manufacturers for distribution through authorized wholesalers to participating facilities. The scope encompasses complete pharmaceutical supply chain management, including product registration with specific National Drug Codes (NDC), compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and maintenance of contractual relationships with primary distribution channels. Issuing bodies include multistate cooperative purchasing alliances, state departments of administration, and participating state and local government health and correctional facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802). The solicitation required vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, EDI capability at 5 percent, administrative fee compliance at 5 percent, and administrative format adherence at 5 percent. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, with performance penalties ranging from $200 to $1,500 per violation for late reporting or onboarding failures. MMCAP reserves awards based on therapeutic considerations, product availability, and member-specific needs across participating states including Minnesota and Oregon.